Assessment of the response to neoadjuvant chemotherapy in osteosarcoma
ZHANG Yun
CUI Jianling
Abstract：Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with an estimated incidence of 3 cases/million population per year. The prognosis is very poor because of pulmonary metastasis.With neoadjuvant chemotherapy, the therapeutic efficacy of osteosarcoma has been greatly improved since 1970s, five-year disease-free survival rate has been raised from less than 20%to 60%-70%, and limb salvage rate has been increased to more than 80%. The neoadjuvant chemotherapy has been shown to be the most significantly prognostic factor in patients with osteosarcoma. Thus, neoadjuvant chemotherapy evaluation methods are becoming a hot topic. This review summarized the evaluation methods of neoadjvant chemotherapy in recent years.
Keywords：OsteosarcomaNeoadjuvant chemotherapyEvaluationNecrosis rateVolumeADC value
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 281-284 )